Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP.
Amylin is secreted with insulin from the pancreas during and after food intake. One of the most potent actions of amylin in vivo is its anorectic effect, which is directly mediated by the area postrema (AP), a circumventricular organ lacking a functional blood-brain barrier. As we recently demonstrated, amylin also stimulates water intake most likely via its excitatory action on subfornical organ (SFO) neurons. Neurons investigated under equal conditions in an in vitro slice preparation of the rat AP were 15-fold more sensitive to amylin than SFO neurons. Amylin (10(-11)-10(-8) M) excited 48% of 94 AP neurons tested; the remaining cells were insensitive. The average threshold concentration of the excitatory response was 10(-10) M and, thus, close to physiological plasma concentrations. Coapplication of the amylin receptor antagonist AC-187 reduced amylin's excitatory effect. Amylin-mediated activation of AP neurons and antagonistic action of AC-187 were confirmed in vivo by c-fos studies. Peripherally applied amylin stimulated cGMP formation in AP and SFO neurons, as shown in immunohistochemical studies. This response was independent of nitric oxide (NO) formation in the AP, while coapplication of the NO synthase inhibitors N-monomethyl-L-arginine (100 mg/kg) and nitro-L-arginine methyl ester (50 mg/kg) blocked cGMP formation in the SFO. In contrast to the SFO, where NO-dependent cGMP formation seems to represent a general inhibitory transduction pathway, cGMP acts as an excitatory second messenger in the AP, since the membrane-permeable analog 8-bromo-cGMP stimulated 65% of all neurons tested (n = 17), including seven of nine amylin-sensitive neurons (77%). The results indicate that the anorectic effect of circulating amylin is based on its excitatory action on AP neurons, with cGMP acting as a second messenger.
Riediger
T
T
Max Planck Institute for Physiological and Clinical Research, W. G. Kerckhoff Institute, 61231 Bad Nauheim, Germany. triedig@vetphys.unizh.ch
Schmid
H A
HA
Lutz
T
T
Simon
E
E
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000682:Amyloid / Q000494:pharmacology*; D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000494:pharmacology; D016762:Genes, fos / Q000187:drug effects; D066298:In Vitro Techniques; D058228:Islet Amyloid Polypeptide; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology*; D019323:omega-N-Methylarginine / Q000494:pharmacology
D000682:Amyloid; D058228:Islet Amyloid Polypeptide; D010446:Peptide Fragments; D010455:Peptides; C087166:AC 187; D019323:omega-N-Methylarginine; C016276:8-bromocyclic GMP; D006152:Cyclic GMP; D015056:1-Methyl-3-isobutylxanthine